Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05571969 · ClinicalTrials.gov registry record · Phase 1
Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Allarity Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT05571969 is a Phase 1 study that was terminated before completion, run by Allarity Therapeutics. The registered enrollment target is 14 participants.
The verdict
NCT05571969, a Phase 1 study, was terminated before completion, sponsored by Allarity Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a Phase Ib, two-part, multi-center study. In Part 1, the study will evaluate the safety and tolerability, antitumor activity, pharmacokinetics, and determine the maximum tolerated dose (MTD) of 2X-121 monotherapy (at BID regimen) in patients with advanced solid tumors. In Part 2, the study will evaluate safety and tolerability, antitumor activity, pharmacokinetics and determine the MTD of dovitinib when given in combination with the MTD of 2X-121 determined in Part 1.
Interventions
- DRUG 2X-121 600 mg
- DRUG 2X-121 800 mg
- DRUG 2X-121 1000 mg
- COMBINATION_PRODUCT 2X-121 + 300 mg dovitinib
- COMBINATION_PRODUCT 2X-121 + 400 mg dovitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2023-03-08 |
| Est. Completion | 2024-10-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05571969
The ClinicalTrials.gov registry entry for NCT05571969 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allarity Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 2X-121 600 mg is the first listed.
NCT05571969 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05571969 about?
NCT05571969 is a clinical study titled "Study of PARPi 2X-121 as Monotherapy and in Combination With Dovitinib in Patients With Advanced Solid Tumors". This is a Phase Ib, two-part, multi-center study. In Part 1, the study will evaluate the safety and tolerability, antitumor activity, pharmacokinetics, and determine the maximum tolerated dose (MTD) of 2X-121 monotherapy (at BID regimen) in patients with advanced solid tumors. In Part 2, the study w...
What is the current status of trial NCT05571969?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2023-03-08. Estimated completion is 2024-10-07.
What interventions are being tested in trial NCT05571969?
The interventions under investigation include: 2X-121 600 mg (DRUG), 2X-121 800 mg (DRUG), 2X-121 1000 mg (DRUG), 2X-121 + 300 mg dovitinib (COMBINATION_PRODUCT), 2X-121 + 400 mg dovitinib (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05571969?
This trial is sponsored by Allarity Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.